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Abstract
Introduction: Although diuretics are mainly used for the treatment of acute decompensated heart failure (ADHF), 
inadequate responses and complications have led to the use of extracorporeal ultrafiltration (UF) as an alternative 
strategy for reducing volume overloads in patients with ADHF.
Objective: The aim of our study is to perform meta-analysis of the results obtained from studies on extracorporeal 
venous ultrafiltration and compare them with those of standard diuretic treatment for overload volume reduction in 
acute decompensated heart failure.
Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials databases were systematically searched 
using a pre-specified criterion. Pooled estimates of outcomes after 48 h (weight change, serum creatinine level, and all-cause 
mortality) were computed using random effect models. Pooled weighted mean differences were calculated for weight loss 
and change in creatinine level, whereas a pooled risk ratio was used for the analysis of binary all-cause mortality outcome.
Results: A total of nine studies, involving 613 patients, met the eligibility criteria. The mean weight loss in patients who 
underwent UF therapy was 1.78 kg [95% Confidence Interval (CI): −2.65 to −0.91 kg; p < 0.001) more than those who 
received standard diuretic therapy. The post-intervention creatinine level, however, was not significantly different (mean 
change = −0.25 mg/dL; 95% CI: −0.56 to 0.06 mg/dL; p = 0.112). The risk of all-cause mortality persisted in patients 
treated with UF compared with patients treated with standard diuretics (Pooled RR = 1.00; 95% CI: 0.64–1.56; p = 0.993).
Conclusion: Compared with standard diuretic therapy, UF treatment for overload volume reduction in individuals suffering 
from ADHF, resulted in significant reduction of body weight within 48 h. However, no significant decrease of serum 
creatinine level or reduction of all-cause mortality was observed. (Arq Bras Cardiol. 2015; 104(5):417-425)
Keywords: Heart Failure / therapy; Hemofiltration; Ultrafiltration; Diuretics.
Introduction
Acute decompensated heart failure (ADHF) is one of the 
leading causes of hospitalization in the U.S. A vast majority of 
these patients admitted to the hospital has to be treated for 
volume overload1,2. Volume overload is frequently associated 
with poor prognosis in heart failure (HF) patients; therefore, 
current medical guidelines recommend non-pharmacological 
and pharmacological interventions to treat volume overload3,4.
Therapeutical ly for reducing overload volume, 
ADHD patients are treated with diuretics administered 
intravenously3,5. However, chronic use of diuretics has been 
associated with negative neuro-hormonal effects7 and may 
cause diuretic resistance.6 Diuretic resistance is associated 
with poor prognosis and higher incidence of morbidity in 
HF patients8.
Extracorporeal Venous Ultrafiltration (UF)—an invasive 
procedure—may be used as an effective alternative 
approach to reduce volume overload in patients resistant 
to conventional diuretics9-12. However, the benefits of UF 
therapy is not very clear. In a randomized trial conducted 
recently, UF failed to produce better efficacy than that 
produced by diuretics and was also associated with an 
increased rate of adverse events13. In contrast, our recent 
findings form meta-analysis data by incorporating the results 
of one recent study suggested that UF may be effective in 
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reducing volume overload, however we have not considered 
results from some studies reported very recently14.
Therefore, in this present study, we seek to evaluate and 
compare the study results obtained using UF and intravenous 
diuretics as treatment options for treating ADHF. Our primary 
objective is to compare weights and measure changes in 
creatinine level in patients who were undergoing treatment 
with UF or diuretics. Our secondary objective is to evaluate 
any potential differences in all-cause mortality rates.
Methods
Following a pre-specified protocol, we systematically 
searched the databases of MEDLINE, EMBASE, and the 
Cochrane Central Register of Controlled Trials; we started from 
the beginning of each database and collected data till May 8th, 
2013. The search strategy included all manuscripts published 
in English. Keywords used for searching were “ultrafiltration,” 
“heart failure,” and “clinical trials.” The retrieved references 
were manually searched for relevant publications and references 
from the included publications were further searched for 
potential relevant studies. Two reviewers independently 
evaluated and retrieved articles using pre-specified criteria 
(EB, MSB). Disagreements were resolved by consensus. 
The reasons for exclusions were systematically logged (Figure 1). 
Our approach strictly adheres to the guidelines set forth 
by Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA)15.
Eligibility criteria
Studies in all languages were considered eligible if it 
would meet the following criteria: 1) prospective 2) included 
hospitalized patients over 18 years of age with clinical 
evidence of acute ADHF; the clinical characteristics of ADHF 
included the presence of orthopnea or paroxysmal nocturnal 
dyspnea [PND], jugular venous pressure [JVP] > 10 cm Hg, 
pulmonary edema or effusion on chest X-ray, left ventricular 
end diastolic pressure > 20 mm Hg, ascites, presacral, and 
edema or the patient have met the criteria set forth by 
New York Heart Association Heart Failure classification III 
or IV during hospital admission or have displayed cardio 
renal syndrome requiring hospitalization 3) UF therapy was 
initiated within 48 hours of hospitalization 4) UF intervention 
was compared with the standard intravenous or oral diuretic 
therapy 5) reported primary weight loss, change in serum 
creatinine level and all-cause mortality as primary outcomes 
during the study period. We excluded studies related to 
non-human subjects, studies without a control group, and 
studies in which UF was performed as an adjunctive therapy. 
Data Extraction
Two authors (CKS and JO) independently extracted data 
from each study included in the analysis and all discrepancies 
were resolved by consensus. The extracted data included 
the year of publication, study country, inclusion and 
exclusion criteria, patient demographics for both groups 
(the number of individuals in each group, age, race, gender, 
and co-morbidities at baseline), quality indicators (details of 
randomization, data analysis, and sample size calculations), 
average weight (expressed in kilogram) at the start and end 
of the study period, average change in weight (when both 
values were not available), average measured creatinine 
level (expressed in mg/dL) at baseline along with follow up, 
average change in creatinine level (when both values were 
not available), and death.
Figure 1 – QUORUM flow diagram detailing the process of determining eligible randomized control trials (RCTs) for inclusion in meta-analysis.
Articles identified in literature search for
title and abstract review
(n = 460)
Potentially articles retrieved for full review
(n = 36)
Trials included in the final analysis
(n = 9)
Studies excluded (n = 424)
 Duplicates (n = 125)
Not revelant to question/reviews
(n = 265)
Other Languages (n = 34)
Studies excluded (n = 27):
No control group (n = 21)
Incomplete data (n = 6)
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Statistical Analysis
Pooled estimates for the outcomes—weight change, 
change in creatinine level, and the risk for all-cause mortality 
were computed using random effect models of Der Simonian 
and Laird16. Pooled weighted mean differences (WMD) 
were calculated for weight loss and change in creatinine 
level whereas a pooled risk ratio was derived for binary 
mortality. Heterogeneity across studies was assessed using 
the Q-test and I2 statistics17. Publication bias was evaluated 
statistically using the Egger’s and Begg’s tests and visually 
using Egger’s plots18.
We performed sensitivity analysis by systematically 
excluding each study sequentially to assess trends in study 
estimates of each individual study that contributed to the 
pooled estimates during the study period. Stratified analysis 
was performed to account for heterogeneity for the outcomes 
related to weight loss and change in creatinine level. 
We also performed additional stratified analyses on treatment 
intention versus per protocol analysis, randomized versus 
non-randomized studies, and larger versus smaller sample 
size. For performing stratified analyses, we have considered 
the following risk factors: diabetes, coronary artery disease 
at baseline, age, gender, and the concentration of B-type 
natriuretic peptide (BNP). We divided the study results 
into two groups based on the median value indicating 
the prevalence of the risk factors, and further evaluated 
the heterogeneity within groups. The studies were further 
stratified according to median values obtained for creatinine 
levels for examining heterogeneity in the outcome related 
to weight change. Similar stratification was implemented for 
examining heterogeneity in measuring changes of creatinine 
levels by using the median values obtained for weight change 
measurements. All statistical analyses were performed using 
Stata version 12 (College Station, TX). We used α = 0.05 for 
analyzing significant differences between different treatment 
groups with regard to meta-relative risks (mRR) and WMD.
Results
Description of Studies
Nine studies met our inclusion and exclusion criteria 
and were incorporated in this meta-analysis (Table 1)19-21. 
Of all eligible studies that met our predefined search 
criterion (n = 36), 21 were excluded because they lacked 
a control group and six were excluded due to incomplete 
data (Figure 1). One study22 had overlapping patient 
population with a larger trial23, and its data were only used 
when information was not reported in the larger study. 
The primary outcomes—change in weight and the change in 
creatinine level starting from baseline values were reported 
in seven studies. The secondary outcome—all-cause 
mortality was reported in six studies. A total of 613 patients 
were included; the control group consisting of 306 patients 
and the UF group consisting of 307 patients.
All studies were published during the year 2005 or later. 
Eight out of nine studies were related to clinical trials, and 
only one was a retrospective observational study. Of the six 
randomized studies selected, three studies were prospective 
clinical trials with an intention to treat analysis. The eligible 
trials were not blinded and treatment allocation concealment 
methods were not used. Three studies reported using the 
Aquadex system for ultrafiltration and one study used PRISMA 
system for ultrafiltration. The remaining studies did not mention 
the device used for ultrafiltration. Furthermore, sample size 
calculation was performed in three studies. Quality assessments 
of the selected studies are presented in (Table 2).
The mean age of patients ranged from 43 to 70 years in 
the control arm and from 52 to 72 years in the intervention 
arm. The majority of patients in both treatment groups were 
men (range 60% to 88% for control arm, range 70% to 88% 
for UF arm) and caucasian (range 30%–94% for control arm, 
range 55%–77% for UF arm). The incidence of diabetes 
varied across studies ranging from 29% to 67% among control 
patients and 30% to 78% among UF patients (Table 1).
Meta-Analysis and Assessment of Bias 
In the pooled analysis, significant increase in weight 
loss was observed between the two groups after 48 hours 
of treatment [1.78 kg difference; 95% Confidence Interval 
(CI): −2.65 to −0.91 kg; p < 0.001] (Figure 2A). However, 
post-intervention reduction in creatinine level failed to 
demonstrate a significant difference between the two 
groups (0.25 mg/dL; 95% CI: 0.56–0.06 mg/dL; p = 0.112) 
(Figure 2B). Finally, no significant difference was observed 
for all-cause mortality in patients treated with UF compared 
with those treated with diuretics (Pooled RR = 1.00; 95% 
CI: 0.64–1.56; p = 0.99) (Figure 2C).
There was evidence of heterogeneity with respect to weight 
change (Q-test p = 0.006; I2 = 64%) and change in creatinine 
level (Q-test p = 0.0003; I2 = 76%), but not for all-cause 
mortality (Q-test p = 0.827; I2 = 0). Additionally, we found 
no evidence of publication bias among weight loss estimates 
(Egger’s test p = 0.09; Begg’s test p = 0.45). However, there 
was visual evidence of publication bias based on symmetrical 
distribution of study estimates on the funnel plot (Figure 3A). 
While there was no statistical evidence of publication bias for 
change in creatinine levels (Egger’s test p = 0.083, Begg’s test 
p = 0.453), visual inspection revealed asymmetric distribution 
of study estimates (Figures 3B). This was also true for all-cause 
mortality outcomes (Egger’s test p = 0.083, Begg’s test 
p = 0.453) (Figure 3C).
Stratified Analysis
The results remained heterogeneous for weight change 
outcomes upon stratification by gender, age, diabetes, coronary 
artery disease (CAD), and creatinine level. After stratification 
by BNP, only studies corresponding to higher values of BNP 
remained heterogeneous. Studies with lower BNP values 
showed significant reduction in weight without notable 
heterogeneity. Similar findings were noted for studies where 
BNP values were not reported (Figure 4).
When stratified by intention-to-treat versus per-protocol 
analysis, the intention-to-treat studies demonstrated no benefit 
with regard to weight reduction with significant heterogeneity 
(p = 0.001) (Figure 5A). In addition, the per-protocol studies 
demonstrated significant weight reduction with virtually no 
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Table 1 – Demographic characteristics of the studies included in the meta-analysis
First author Bart Costanzo Libetta Bartone Rogers Giglioli Bart Badawy Hanna
Year 2005 2007 2007 2008 2008 2011 2012 2012 2012
Journal JACC JACC NDT CHF JCF EJHF NEJM JCC CHF
country USA USA Italy USA USA Italy USA Egypt USA
Trial RAPID-CHF UNLOAD - - UNLOAD ULTRADISCO CARESS-HF Un-named Un-named
Sample size 40 200 10 50 19 30 188 40 36
Age - Control 69.5 63 ± 14 43.3 ± 11.6 66.8 ± 14.3 64 ± 15 65.8 ± 18.4 66 62 ± 14 59 ± 15.5
Age - UF 67.5 62 ± 15 51.5 ± 9.4 66.6 ± 14.4 54 ± 16 72.4 ± 14.1 69 64 ± 11 60 ± 9.1
Male (%) - Control 70% 70% NA 68% 60% 87% 72% 60% 76%
Male (%) – UF 70% 68% NA 68% 78% 87% 78% 80% 85%
White race control NA 52% NA NA 30% NA 71% NA 94%
White race UF NA 55% NA NA 56% NA 77% NA 73%
Diabetes control (%) 53% 49% NA 52% 50% 60% 67% 55% 29%
Diabetes UF (%) 30% 5% NA 68% 78% 40% 65% 60% 37%
CAD (%) control 30% 48% NA 60% 60% 60% 51% 65% 29%
CAD (%) UF 30% 56% NA 76% 78% 60% 70% 60% 21%
Weight loss control (Kg) 1.9 ± 1.2 3.1±3.5 NA 2.9 ± 3.4 1.9 ± 2.2 6.9 ± 1.8 5.5 ± 5.1 3.7 ± 3.2 1.0 ± 2.5
Weight loss UF (Kg) 2.5 ± 1.2 5 ± 3.1 NA 7.1 ± 6.2 2.7 ± 2.6 9.1 ± 1.7 5.7 ± 3.9 6.3 ± 3.5 4.7 ± 3.5
Creatinine control at baseline 1.8 1.5 ± 0.5 1.2 ± 0.5 1.8 ± 0.8 1.6 ± 0.8 1.9 ± 0.6 2.1 1.4 ± 0.7 1.7 ± 0.8
Creatinine UF at baseline 1.6 1.5 ± 0.5 1.9 ± 1.6 1.9 ± 0.8 1.8 ± 0.8 2.2 ± 0.8 1.9 1.4 ± 0.8 1.6 ± 0.7
Change in creatinine control 0.1 0.0 ± 0.41 0.1 ± 1.65 0.11 ± 0.15 0.07 ± 0.63 -0.04 ± 0.53 0.2 ± 0.92 0.0 ± 0.8
Change in creatinine UF 0.3 -0.3 ± 1.2 -0.9 ± 0.96 -0.01 ± 0.31 -0.6 ± 0.75 0.23 ± 0.7 -0.4 ± 0.71 0.2 ± 0.7
Death control 0 (0%) 11 (11%) NA 0 (0%) NA NA 13 (13% 5 (25%) 4 (24%)
Death UF 1 (5%) 9 (9%) NA 1 (4%) NA NA 16 (17%) 3 (15%) 4 (21%)
BNP control NA 1309 ± 1494 370.6 ± 148.8 826 ± 913 NA 6707 ± 3597 4007 8946 ± 5981
BNP UF NA 1256 ± 1203 706.3 ± 205.6 1066±1196 NA 5063 ± 3811 5013 8256 ± 8580
UF: donates Extracorporeal Venous Ultrafiltration; CAD: donates coronary artery disease; BNP: donates B-type natriuretic peptide.
heterogeneity (p = 0.46). Similarly, change in creatinine level 
was significantly higher in the intention-to-treat studies, but 
significantly lower in the per-protocol studies (Figure 5B). 
The data remained heterogeneous and non-statistically 
significant after stratification by randomized versus 
non-randomized studies and larger versus smaller sample size.
Sensitivity Analysis
Sensitivity analysis, revealed no evidence of changing 
magnitude in the pooled estimates for weight change over 
time. However, there may have been trends toward the null 
for change in creatinine levels and over-all mortality outcome 
during the study period. Exclusion of studies published after 
2008 resulted in varying differences in the pooled estimates 
for the WMD associated with change in creatinine levels and 
weight loss; however the exclusion did not have a significant 
impact on the pooled estimates given the overlapping 95% 
confidence intervals with full-pooled effects when data from 
all studies were included for analyzing the outcomes—weight 
change and change in creatinine levels.
Discussion
The present analysis evaluated the clinical responses 
of UF treatment for reducing volume overload in ADHF 
patients and have compared the outcomes with that of 
standard diuretic approach. Our study demonstrated that 
a significant difference existed for change in mean body 
weight between the two treatment groups, but no significant 
difference was observed with regard to change in creatinine 
levels. Additionally, the mortality rates were similar in 
the two groups during the follow-up period. Hence this 
meta-analysis does not support prior observations that UF 
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Figure 3 – A: Funnel plot for visualization of publication bias across studies related to weight loss. B: Funnel plot for visualization of publication bias across studies related 
to change in creatinine level. C: Funnel plot for visualization of publication bias across studies related to mortality outcome.
Funnel pior with pseudo 95% confidence limits
0
0.2
0.4
0.6
-1 -0.5 0 0.5 1
theta
C
s.e
. o
f t
he
ta
Funnel piot with pseudo 95% confidence limits
0
0.2
0.4
0.6
-1 -0.5 0 0.5 1
theta
B
s.e
. o
f t
he
ta
Funnel plot with pseudo 95% confidence limits
-1.5 -1 -0.5 0 0.5
0.5
0.4
0.3
0.2
0.1
0
A
theta
s.e
. o
f t
he
ta
Figure 2 – A: Forest plot comparing mean weight difference between the control and the intervention group. Squares represent weighted mean difference (kg) of patient’s 
weight in the UF versus control group. B: Forest plot comparing mean difference in creatinine level between the control and the intervention group. Squares represent 
weighted mean difference (mg/dL) of creatinine level in the UF versus control group. C: Forest plot comparing relative risk of overall mortality. Squares represent relative 
risk of death in the UF versus control group. Size of square is proportional to study weight. Error bars represent 95% confidence interval. Diamonds represent pooled 
estimate for risk ratio with 95% CI.
Weighted Mean Difference of Weight (kg) 48h
after Venous Ultrafiltration
Badawy
Bart 2005
Bart 2012
Bartone
Constanzo
Giglioli
Hanna 2012
Rogers
Overall
(I-squared = 66.8%, p = 0.004)
NOTE: Weights are from random effects analysis
-7.07 0 7.07
Study ID WMD (95% CI)
-2.60 (-4.68, -0.52)
-0.64 (-1.38, 0.10)
-0.20 (-1.50, 1.10)
-4.30 (-7.07, -1.54)
-1.90 (-2.82, -0.98)
-2.20 (-3.45, -0.95)
-3.70 (-5.67, -1.73)
-0.80 (-2.98, 1.38)
-1.78 (-2.65, -0.91)
A
Libetta
Bartone
Rogers
Giglioli
Bart 2012
Badawy
Hanna 2012
Overall squared(I- = 80.1%, p = 0.000)
Study ID WMD (95% CI)
-0.30 (-1.38, 0.78)
-1.00 (-1.75, -0.25)
-0.12 (-0.34, 0.10)
-0.67 (-1.16, -0.18)
0.27 (0.09, 0.45)
-0.60 (-1.11, -0.09)
0.20 (-0.29, 0.69)
-0.25 (-0.59, 0.09)
-1 0 1
Weighted Mean Change in Creatinine (mg/dL) at follow up
B
All Cause Mortality According to Treatment
Study ID RR (95% CI)
Bart 2005
Constanzo
Bartone
Bart 2012
Badawy
Hanna 2012
Overall squared(I- = 0.0%, p = 0.827)
3.00 (0.13, 69.52)
0.82 (0.35, 1.89)
3.00 (0.13, 70.30)
1.23 (0.63, 2.41)
0.60 (0.17, 2.18)
0.89 (0.26, 3.04)
1.00 (0.64, 1.56)
0.1 1 10
C
Table 2 – Quality assessment of studies included in the Meta analysis 
Author Randomization Allocation concealment Blinding
Intention to treat 
analysis
Sample size 
calculation Design
Bart 2005 Yes No No Yes Yes RCT
Constanzo Yes No No No No RCT
Libetta No No No No No Non-randomized controlled trial
Bartone No No No No No Retrospective cohort 
Rogers Yes No No No No RCT
Giglioli Yes No No No Yes RCT
Bart 2012 Yes No No Yes Yes RCT
Badawy Yes No No No No RCT
Hanna Yes No No Yes Yes RCT
RCT: randomized control trials
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Figure 4 – A: Results showing mean change in weight after 48 hours stratified by baseline BNP values. B: Results showing mean change in creatinine level stratified 
by baseline BNP values.
Study WMD (95% CI)
Intention-to-treat
Bart 2005
Bart 2012
Hanna 2012
Subtotal
(I-squared = 85.8%, p = 0.001)
Per-protocol
Badawy
Bartone
Constanzo
Giglioli
Rogers
Subtotal
(I- = 0.0%, p = 0.461)squared
-2 0 2
-0.54 (-1.17, 0.09)
-0.04 (-0.33, 0.24)
-1.21 (-1.92, -0.49)
-0.54 (-1.21, 0.14)
-0.78 (-1.42, -0.13)
-0.86 (-1.44, -0.28)
-0.57 (-0.86, -0.29)
-1.26 (-2.04, -0.47)
-0.33 (-1.24, 0.57)
-0.68 (-0.90, 0.46)
-0.39 (-0.81, 0.02)
Standardized Mean Difference of Weight 48 after Venous Ultrafiltration
A B
Weighted Mean Difference of Creatinine (mg/dL) after Treatment
Study WMD (95% CI)
0.27 (0.09, 0.45)
0.20 (-0.29, 0.69)
0.26 (0.09, 0.43)
-0.60 (-1.11, -0.09)
-1.00 (-1.75, -0.25)
-0.67 (-1.16, -0.18)
-0.30 (-1.38, 0.78)
-0.12 (-0.34, 0.10)
-0.49 (-0.84, -0.13)
Intention-to-treat
Bart 2012
Hanna 2012
Subtotal
(I- = 0.0%, p = 0.794)squared
Per-protocol
Badawy
Bartone
Giglioli
Libetta
Rogers
Subtotal
(I- = 57.2%, p = 0.053)squared
-2 0 2
NOTE: Weights are from random effects analysis
treatment option may improve volume overload, renal 
dysfunction or mortality rate in comparison with standard 
therapy using diuretics.
While some studies demonstrated that treatment with 
UF significantly reduced volume overload compared with 
traditional diuretic approach alone9,23, findings from a more 
recent study contradicted these results13. The latter study 
included patients with severe renal dysfunction, and suggested 
that the need for early discontinuation of UF treatment due 
to clinical and technical reasons other than volume reduction 
was responsible for its failure to provide any beneficial effect 
with respect to weight change and lowering of creatinine 
levels. The same study also demonstrated that UF treatment 
was associated with an increased rate of adverse events such 
as subsequent kidney failure, bleeding, and catheter-related 
complications. Our analysis contradicted previous findings 
on weight loss. However, this was mainly observed in the 
studies dealing with lower BNP concentration and per protocol 
analysis. While the studies with intention-to-treat analysis 
demonstrated no significant changes in weight reduction, we 
detected a small significant increase in the creatinine levels. 
In clinical practice, the benefit of UF was restricted to those 
who were able to tolerate this therapy. Not only was the weight 
reduction benefit small, any benefit from this therapy appears 
to be restricted only to those individuals, who could tolerate 
this therapy such as individuals in the per protocol analysis as 
well as individuals with lower BNPs, who are also less likely 
to need advanced support.
Figure 5 – A Results showing mean change in weight after 48 hours stratified by intention-to-treat versus per-protocol analysis. B: Results showing mean change in 
creatinine level stratified by intention-to-treat versus per-protocol analysis.
Standardized Mean Difference of Weight 48 after Venous Ultrafiltration
Study WMD (95% CI)
No BNP Measures
Badawy
Bart 2005
Rogers
Subtotal
(I-squared = 0.0%, p = 0.722)
Lower BNP
Bartone
Constanzo
Subtotal
(I-squared = 0.0%, p = 0.383)
Higher BNP
Bart 2012
Giglioli
Hanna 2012
Subtotal
(I-squared = 90.5%, p = 0.000)
NOTE: Weights are from random effects analysis
-2 0 2
-0.78 (-1.42, -0.13)
-0.54 (-1.17, 0.09)
-0.33 (-1.24, 0.57)
-0.59 (-0.99, -0.19)
-0.86 (-1.44, -0.28)
-0.57 (-0.86, -0.29)
-0.63 (-0.88, -0.38)
-0.04 (-0.33, 0.24)
-1.26 (-2.04, -0.47)
-1.21 (-1.92, 0.49)
-0.01 (-1.11, 1.09)
A
Weighted Mean Difference of Creatinine (mg/dL) after Treatment
NOTE: Weights are from random effects analysis
Study WMD (95% CI)
-2 0 2
B
No BNP Measures
Lower BNP
Higher BNP
Subtotal
(I-squared = 65.1%, p = 0.091)
Subtotal
(I-squared = 7.6%, p = 0.298)
Subtotal
(I-squared = 83.9%, p = 0.002)
Badawy
Rogers
Bartone
Libetta
Bart 2012
Giglioli
Hanna 2012
-0.60 (-1.11, -0.09)
-0.12 (-0.34, 0.10)
-0.30 (-0.76, 0.15)
-1.00 (-1.75, -0.25)
-0.30 (-1.38, 0.78)
-0.76 (-1.41, -0.12)
0.27 (0.09, 0.45)
-0.67 (-1.16, -0.18)
0.20 (-0.29, 0.69)
-0.04 (-0.59, 0.51)
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The small change in weight detected in both groups can 
be explained in several ways. First, both therapies might 
not have been adequately fine-tuned to obtain maximum 
benefit. Second, patients might be too unstable or refractory 
to tolerate a more aggressive intervention. Lastly, patients 
might not be completely overloaded with fluid, as one would 
expect and as such not enough volume was lost in both 
groups. Although our meta-analysis is unable to fully answer 
this question, since the benefit was restricted to those studies 
that reported lower BNP values, it seems that the difference 
in weight loss was restricted to the less decompensated 
group of patients. Hence, we may suggest that severe cases 
of ADHF might not have tolerated more aggressive diuresis, 
regardless of the form of treatment applied.
Interestingly, our study showed that the benefit achieved 
with regard to weight loss and favorable creatinine changes 
were also limited to those studies with lower baseline BNP 
levels. Since BNP is a surrogate marker of ADHF severity, it 
was elevated in all studies. Moreover,, we did not witness 
any intervention benefits in those studies where the mean 
baseline BNP level was above the median value as calculated 
from the studies included in the meta-analysis. This finding 
suggested that the benefit of UF therapy might be restricted 
to those individuals with less severe ADHF and who could 
tolerate this therapy. However, this was also the group in 
which patients could be adequately managed by treatment 
with diuretics, and they did not require any advanced 
specialized care such as UF.
In addition, our study demonstrated that diuretics and 
UF therapeutic options had similar benefits with regard to 
overall mortality rate. This finding was not surprising since 
the most common causes of death in individuals with ADHF 
are sudden cardiac death due to arrhythmias, low-output 
states refractory to inotropic support, and infection; both 
interventions are intended for volume reductions and as 
such have no direct influence in reducing these outcomes.
Our study has several limitations. First, the heterogeneity 
in the results obtained for weight and change in creatinine 
level could only be partially explained by the stratified 
analysis although other study characteristics might explain 
our current findings. Second, our study did not account 
for variations stemmed from the designed dosage regimen 
of diuretics or the duration of UF and the variations might 
influence the overall disease prognosis. Finally, there 
are limitations in the studies selected such as allocation 
concealment or blinding or randomization, and only a few 
were analyzed in the intention-to treat analysis.
Although some of these subjects were addressed in 
the stratified analysis, residual confounding might still be 
present. Furthermore, just two of the nine total studies 
contributed 388 (63%) patients for analysis, although 
sensitivity analysis revealed that no single study had 
excessive influence on the results. Despite these limitations, 
our study has several strengths. First, our systematic 
literature search included all available scientific evidence 
and thereby reduces the likelihood of biased conclusions 
regarding clinical benefits of one treatment versus the 
other. Second, a homogeneous lack of all-cause mortality 
benefit was considered for both therapies. Finally, our work 
corroborated findings from existing literature by indicating 
that the benefits of UF might be limited to particular 
subgroups with favorable risk profiles.
Conclusion
Compared with standard therapy using diuretics, the use of 
UF in treating volume overload in ADHF was only moderately 
effective in reducing weight. However, we neither observed 
any significant reduction of serum creatinine level nor 
observed any improvement in the overall all-cause mortality 
rate. Though UF therapy might cause improvement in the 
fluid loss in selected populations, UF should not be universally 
recommended over standard therapy using diuretics in 
managing fluid status in ADHF patients particularly considering 
the lack of clear evidence supporting its beneficial effects 
coupled with the high cost associated with its use.
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